PIPELINE

Antapodia Biotherapeutics uses state-of-the-art lipid nanoparticles (LNPs) to deliver small interfering RNAs (siRNAs) that work in concert to inhibit invadopodia formation in invasive cancer cells. The company's first-in-class anti-invadopodia cancer gene therapy, AP-01, specifically targets a cancer-specific transcript variant of MIR-01 to inhibit invadopodial biogenesis, thereby halting cancer spreading and metastasis (Figure 1). The company also develops first-in-class invadopodia-targeted monoclonal antibodies (mAbs) AP-02 and AP-03, which specifically blocks the invadopodia-surface proteins MIR-02 and MIR-03, respectively. The company has completed a series of POM/POC studies to demonstrate the remarkable anti-tumor and anti-metastasis efficacy of these novel and powerful invadopodia-targeted therapies.

PIPELINE

Product (target diseases)

AP-01 (LNP-siRNA)

(TNBC, HCC, IHCC)

Molecular target/biomarker

MIR-01

 

POC/POM studies > In vitro testing > In vivo testing > Toxicity > IND enabling

Product (target diseases)

AP-02 (mAb)

(CRPC, PDAC)

Molecular target

MIR-02

 

POC/POM studies > In vitro testing > In vivo testing > Toxicity > IND enabling

Product (target diseases)

AP-03 (mAb)

(CRPC, PDAC)

Molecular target

MIR-03

 

POC/POM studies > In vitro testing > In vivo testing > Toxicity > IND enabling

AP: Antapodia; LNP: lipid nanoparticle; MIR: Master Invadopodial Regulator; TNBC: triple-negative breast cancer; HCC: hepatocellular carcinoma; IHCC: intra-hepatic cholangiocarcinoma; mAb: monoclonal antibody; CRPC: castration-resistant prostate cancer; PDAC: pancreatic ductal adenocarcinoma.

Figure 1. The MoA of the invadopodia-targeted siRNA therapy AP-01

moa-of-ap-01-1000-px.png

A panel of siRNAs that specifically target a tumor-specific transcript region of MIR-01 are encapsulated in LNPs to make the gene therapy agent AP-01. When delivered to tumors through intratumor (IT), intraperitoneal (IP) or intravenous injections (IV), AP-01 is internalized by invasive cancer cells to inhibit the expression of MIR-01, thereby inhibiting the invadopodia biogenesis and cancer cell invasiveness.

AP-01

AP-01 is a panel of LNP-formulated siRNAs targeting a cancer-specific transcript variant of MIR-01. Since invadopodia regulates the invasive growth of tumor cells in the three-dimensional microenvironment in vivo, and that MIR-01 also critically coregulates Wnt signaling, the downregulation of MIR-01 expression mediated by AP-01 is expected to simultaneously inhibit tumor growth and spreading as well as distant metastases. Systemic administration of AP-01 has been shown to induce a dual blockade of tumor growth and metastasis and significantly lengthens survival. Systemic and/or localized administrations of AP-1 lead to a remarkable tumor shrinkage in ovarious rthotopic and/or PDX models of TNBC and HCC. These compelling POC data underscore the immense therapeutic potential of AP-01 in aggressive and metastatic cancers.

AP-02

AP-02 is a first-in-class invadopodia-targeted mAb that blocks the binding of MIR-02 to its ligand, thereby inhibiting its downstream signaling leading to invadopodia biogenesis. Antapodia Biotherapeutics has completed a series of PoC studies to demonstrate the ability of the systemically administered AP-02 to inhibit or even abolish the development of distant metastasis in mouse models of prostate, pancreatic and gastric cancers, underscoring its therapeutic potential in these types of metastasis cancers.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                

AP-03

AP-03 is another invadopodia-targeted mAb that inhibits the ability of MIR-03 to activate pericellular proteolysis and invadopodia functions. Antapodia Biotherapeutics has completed a series of PoC studies to demonstrate the ability of the systemically administered AP-03 to inhibit or even abolish the development of distant metastasis in mouse models of prostate, pancreatic and gastric cancers, underscoring its therapeutic potential in these types of metastasis cancers.

 

 

 

 

 

 

 

           

Copyright © Antapodia Biotherapeutics, Inc. All Rights Reserved

Search